Article
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
eLife - 28 Oct 2020
Weisblum Yiska, Schmidt Fabian, Zhang Fengwen, DaSilva Justin, Poston Daniel, Lorenzi Julio Cc, Muecksch Frauke, Rutkowska Magdalena, Hoffmann Hans-Heinrich, Michailidis Eleftherios, Gaebler Christian, Agudelo Marianna, Cho Alice, Wang Zijun, Gazumyan Anna, Cipolla Melissa, Luchsinger Larry, Hillyer Christopher D, Caskey Marina, Robbiani Davide F, Rice Charles M, Nussenzweig Michel C, Hatziioannou Theodora, Bieniasz Paul D
Abstract excerpt
Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombinant chimeric...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
